Glaukos Corporation (GKOS) News
Filter GKOS News Items
GKOS News Results
|Event/Time||Symbol||Company||News Detail||Start||End||Change||POWR Rating|
|Loading, please wait...|
Latest GKOS News From Around the Web
Below are the latest news stories about GLAUKOS Corp that investors may wish to consider to help them evaluate GKOS as an investment opportunity.
Glaukos (GKOS) is a long-term holding of mine that has been heavily impacted by the COVID-19 pandemic. Given that the vast majority of Glaukos’ revenue comes from elective surgery, many of the procedures that would have led to product sales for the company just haven’t been taking place. I last...
Glaukos Corporation (GKOS) Q2 2020 Earnings Conference Call August 6, 2020 16:30 ET Company Participants Chris Lewis - Director of Investor Relations, Corporate Strategy & Development Tom Burns - President & Chief Executive Officer Joe Gilliam - Chief Financial Officer Chris Calcaterra - Chief Operating Officer Conference Call Participants Brian...
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2020 financial results after the market close on Thursday, August 6, 2020. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on August 6, 2020.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
Investor confidence is high on Glaukos (GKOS) stock, thanks to solid prospects.
Glaukos (GKOS) has priced its private offering of $250M (from $200M) aggregate principal amount of 2.75% Convertible Senior Notes due 2027.Initial purchasers will have an option to purchase up to an additional $37.5M of notes. The initial conversion rate is 17.8269 common shares per $1,000 principal amount of notes (~$56.10/share)....
Glaukos Announces Presentation Cancellation at the William Blair 40th Annual Growth Stock Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that in light of the company’s offering of its 2.75% Convertible Senior Notes due 2027, which is expected to close on June 11, 2020, subject to customary closing conditions, management will no longer be participating in its previously announced virtual fireside presentation and associated webcast at the William Blair 40th Annual Growth Stock Conference, previously scheduled for Wednesday, June 10, 2020, at 3:20 p.m. CDT. Management will continue to participate in the conference’s other investor forums.
Glaukos Corporation Announces Pricing of Private Offering of $250 Million of 2.75% Convertible Senior Notes
Glaukos Corporation (NYSE: GKOS) (the "Company" or "Glaukos"), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today the pricing of its private offering of $250 million aggregate principal amount of 2.75% Convertible Senior Notes due 2027 (the "notes"). The offering size was increased from the previously announced offering size of $200 million aggregate principal amount of notes. The notes were offered only to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Glaukos has granted to the initial purchasers of the notes a 13-day option to purchase up to a...
Glaukos (GKOS) intends to offer $200M aggregate principal amount of Convertible Senior Notes due 2027 in a private offering.Initial purchasers will have an option to purchase up to an additional $30M of the notes. Interest rate, initial conversion rate and other terms of the notes are not yet determined.Net proceeds...